Open-source workflow automation platform n8n has warned of a maximum-severity security flaw that, if successfully exploited, could result in authenticated remote code execution (RCE). The vulnerability, which has been assigned the CVE identifier CVE-2026-21877, is rated 10.0 on the CVSS scoring...
Non-human employees are becoming the future of cybersecurity, and enterprises need to prepare accordingly. As organizations scale Artificial Intelligence (AI) and cloud automation, there is exponential growth in Non-Human Identities (NHIs), including bots, AI agents, service accounts and...
Security teams are still catching malware. The problem is what they’re not catching. More attacks today don’t arrive as files. They don’t drop binaries. They don’t trigger classic alerts. Instead, they run quietly through tools that already exist inside the environment —...
A new “lung-on-chip” model, consisting solely of genetically identical cells derived from a single person, has advanced our understanding of tuberculosis, opening the door to personalized treatments. Researchers at the Francis Crick Institute (London, UK) and AlveoliX (Bern, Switzerland) have...
Original story from the Aerospace Information Research Institute, Chinese Academy of Sciences (Beijing, China). A new, implantable, ultrasound-based blood pressure monitoring system represents a promising alternative to conventional tools for continuous, unobtrusive blood pressure measurement....
Before we launch into the new year, we are taking a moment to reflect on 2025, including the rising trends we observed and the new feature types we introduced on BioTechniques.com, before wrapping up with our top content from the year. 2025: Under the microscope 2025 saw a dramatic expansion of...
Artificial intelligence is reshaping instruction, cybersecurity threats are becoming more advanced, and digital tools are expanding faster than most districts can keep up with.
Continue reading →
IT security teams, especially the compliance cast, love drama. The slower, more arcane, and less intelligible the script, the louder the applause.
Continue reading →
Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.
Continue reading →